AROA BIOSURGERY LIMITED
ASX:ARXPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 95.5% of what they think they own, once every option and right converts.
No major dilution pressure signals in current disclosures
AROA BIOSURGERY LIMITED's ordinary share count was 346M as of April 2026, representing a 0.3% increase from August 2024. The company has not raised capital in the past 24 months and has no pending proposed issues. Options and rights on issue could convert into 16M new shares, representing 4.7% of the current share count, with no stated expiry date on record. None of these options are currently in the money. As of September 2025, the company reported A$25.4M in available cash, with non-negative net cash flow meaning no funding runway figure applies.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 28 Aug 2026 | 3G · unquoted | ORDINARY FULLY PAID | 345.9M | Appendix 3G |
| 11 Aug 2026 | 3G · unquoted | ORDINARY FULLY PAID | 345.9M | Appendix 3G |
| 11 Aug 2026 | 3H · cancellation | ARX : ORDINARY FULLY PAID | 345.9M | Appendix 3H |
| 28 July 2026 | 3G · unquoted | ARX : ORDINARY FULLY PAID | 345.9M | Appendix 3G |
| 14 July 2026 | 3H · cancellation | ARX : ORDINARY FULLY PAID | 345.9M | Appendix 3H |
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered6.1M · 1.8% of sharesOptions and warrants — they convert when the share price clears their exercise price.No exercise price is on record for any of it, so none of it can be called in or out of the money.
- Condition-triggered10.1M · 2.9% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
Exercise price on record: 0 priced, 16.2M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 16.2M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| ARXAAJ | — | Condition-triggered | — | — | 4.8M | Filing Meeting |
| ARXAAH | Performance rights | Condition-triggered | — | — | 5.3M | Filing Meeting |
| ARXAAK | Options | Price-triggered | — | — | 6.1M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 30 June 2026 | Brian Ward | Sell | — | 453k | — | — | 3Y notice |
| 26 June 2026 | John Diddams | Sell on-market | 1.0M | 20k | — | $126k | 3Y notice |
| 20 Sept 2025 | Brian Ward | Other incentive | 33.1M | 1.4M | 2.0M | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.